What’s new in renal denervation?
Nattawut Wongpraparut
Department of Medicine, Siriraj Hospital
Hypertension is the main contributor to death. Every 20/10-mmHg increase in blood pressure correlated with doubling of 10-year CV mortality. Its currently affected more than 1 billion people worldwide. Significant percentage of patient, who has been treated with current antihypertensive drugs, is in resistant hypertension. We need a new target of treatment. The kidney is source of central sympathetic activity, sending the signal to CNS. Chronic stimulation sympathetic nerve leads to unwanted consequence. Percutaneous renal nerve denervation has been proposed to be a new target and safe approach to reduce sympathetic activity. In simplicity -1 trial, renal sympathetic denervation reduce average systolic BP of 32 mmHg, and diastolic BP of 14 mmHg at 24 months after treatment. This 30 minutes presentation will review 1) the basic physiology central nervous system- renal sympathetic and its contribution of hypertension 2) recent clinical trials of renal denervation in treatment of resistant hypertension 3) recent information of renal denervation and insulin resistant, sleep apnea etc.